Skip to main content
TTRX
NASDAQ Life Sciences

Turn Therapeutics Q2 2026: $5.85M Net Loss, Going Concern Warning, Cash Runway to Q3 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$10.54
Mkt Cap
$313.966M
52W Low
$2.57
52W High
$26.5
52W Position info
310% above low
Off High info
60% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TTRX has more than doubled off its 52-week low of $2.57.

Summary

Turn Therapeutics filed its Q2 2026 10-Q, reporting a $5.85 million net loss and $10.3 million in cash, with management raising substantial doubt about its ability to continue as a going concern. The filing details a $6.1 million derivative liability and the terms of its $25 million debt facility.


Key Events · Earnings and Guidance · TTRX

  • Going Concern Warning

    Management states substantial doubt about the company's ability to continue as a going concern, with cash runway estimated only into Q3 2027.

  • Q2 Net Loss of $5.85M

    Net loss for Q2 2026 was $5.85 million, up from $1.24 million in Q2 2025, driven by a $3.34 million non-cash loss from derivative liability remeasurement.

  • Derivative Liability Surge

    Derivative liability instrument increased to $6.1 million from $3.0 million at year-end, primarily due to a $2.7 million increase in warrant fair value as the stock price rose.

  • Avenue Capital Loan Terms

    The $25 million loan facility includes a $7 million Tranche 1 funded, with a conversion option allowing the lender to convert up to $2 million of principal at 80% of trading price.


Analysis · TTRX · Life Sciences

The 10-Q confirms the Q2 net loss of $5.85 million and cash of $10.3 million, but adds critical detail: management states substantial doubt about the company's ability to continue as a going concern, with cash runway only into Q3 2027. The derivative liability jumped to $6.1 million from $3.0 million, driven by a non-cash warrant remeasurement as the stock price rose. The company also disclosed the terms of its $25 million Avenue Capital loan, including a conversion option at 80% of trading price, and expanded its Phase 2 trial for GX-03. This is a material update for investors assessing the company's survival and dilution risk.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TTRX was trading at $10.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $314M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TTRX - Latest Insights

TTRX
Nov 16, 2026, 4:23 PM EST
Filing Type: 424B3
Importance Score:
7
Price at Filing: $8.55
Real-time Price: $8.00 info
Change: -$0.5475 (-6%) info
Market Cap: $247.486M info
TTRX
Nov 10, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.79
Real-time Price: $8.00 info
Change: -$1.79 (-18%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 8:05 AM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 8:00 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info
TTRX
Nov 09, 2026, 7:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $8.00 info
Change: -$1.48 (-16%) info
Market Cap: $247.486M info